| Bioactivity | Triclabendazole-13C,d3 is the 13C- and deuterium labeled Triclabendazole[1]. |
| Invitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[52]. |
| Name | Triclabendazole-13C,d3 |
| Formula | C1313CH6D3Cl3N2OS |
| Molar Mass | 363.67 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223. [2]. Moll, L., et al., Resistance of Fasciola hepatica against triclabendazole in cattle and sheep in The netherlands. Vet Parasitol, 2000. 91(1-2): p. 153-8. [3]. Robinson, M.W., et al., Triclabendazole-resistant Fasciola hepatica: beta-tubulin and response to in vitro treatment with triclabendazole. Parasitology, 2002. 124(Pt 3): p. 325-38. [4]. Fairweather, I., Triclabendazole: new skills to unravel an old(ish) enigma. J Helminthol, 2005. 79(3): p. 227-34. |